FDA finalizes guidance on validating diagnostic tests for emerging pathogens during a declared emergency
Published November 15, 2026 · Coverage November 8–14, 2026, Pacific · Lower priority
The Food and Drug Administration (FDA) announced on November 10, 2026 a final guidance, Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency. It gives general recommendations for validating in vitro diagnostic devices (IVDs) for emerging pathogens during an applicable declaration of public health emergency (PHE), with a template, and applies to data submitted in a pre-Emergency Use Authorization (EUA) request, an EUA request, or for a test offered under an applicable enforcement discretion policy. The guidance is not binding.
Background
FDA issued the draft guidance in January 2025 (90 FR 1168). The guidance answers recommendations from an October 2021 independent assessment and a September 2022 HHS Office of Inspector General (OIG) report on FDA's COVID-19 testing response.
Who this affects
Hospital and health-system clinical laboratories that develop or validate their own tests during outbreaks.
Why it matters
Inference: hospital laboratories that would bring up their own tests in a future outbreak now have FDA's stated validation expectations in advance, which can shorten an emergency submission.
Recommended action
- Laboratory leadership: compare emergency test validation plans with the final guidance and template.
Scope and timing
- Authority status
- Guidance
- Responsible owner
- Laboratory
- Publication date
- 2026-11-10
- Other dates
- Comments on guidance accepted at any time; draft guidance noticed 2025-01-07 (90 FR 1168)
Not established
The guidance document itself was not read; this entry rests on the Federal Register notice of availability.
Sources
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Compliance Sweep report →